For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Human Interleukin 7 (IL7) is produced as a precursor maturing into a 152 amino acid glycoprotein. IL7 is mainly produced by non-hematopoietic cells like stroma cells in the bone marrow, the thymus, and in lymphoid tissues. IL7 acts mainly on stem cells and induces proliferation and differentiation of pre-B cells, thymocytes and T cell progenitors and co-stimulates proliferation of mature T-cells with other factors such as IL2. It also protects thymocytes from apoptosis through an increased expression of bcl2. IL7 increases the growth, the development, and the anti-viral activity of both CD4+ and CD8+ cells. Clinical results suggest that IL7 is a potential candidate in the treatment of HIV-patients. IL7 is also implicated in rheumatoid arthritis, chronic colitis, and asthma.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Cytokine|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.